


FACTSHEET

Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with our psilocybin-based treatments for chronic pain and other indications

Tryp stands out from other psychedelic drug development companies in four important ways:

1. Unique, highly valuable indications

While mental health indications such as depression, anxiety, and addiction are being pursued by multiple companies, Tryp is breaking new ground in chronic pain and eating disorders. Taken together, the commercial potential of our development programs exceeds \$12 billion in peak annual sales.



PROGRAM	INDICATION	PRECLINICAL	CLINICAL PHARMACOLOGY	PHASE 2B*
TRP-8803	FIBROMYALGIA	▶	▶	▶
	PHANTOM LIMB PAIN	▶	▶	▶
	CRPS	▶	▶	▶
	BINGE EATING DISORDER	▶	▶	▶
	HYPOTHALAMIC OBESITY	▶	▶	▶

▶ CURRENT
▶ NEXT 18 MONTHS

2. A proprietary formulation and delivery method

Our psilocybin-based drug product, TRP 8803, features a proprietary formulation and novel method of administration to improve the patient experience. We have filed a provisional patent to protect the unique features of TRP-8803 foundational piece of intellectual property for Tryp.

*Tryp expects to use preclinical data for TRP-8803, clinical pharmacology data for trp-8803, and phase 2a data for trp-8802 to support the use of trp-8803 in phase 2b clinical trials

3. Exclusive manufacturing

We have secured an exclusive supply of our psilocybin-based active ingredients and drug products, with sufficient quantities of material to support clinical trials and ultimate commercialization—a rare capability among psychedelic drug development companies.



4. The right people at the right time

We have assembled foremost experts in drug development and psychedelics within Tryp while partnering with academic collaborators with unrivaled leadership within their respective indications. Our Scientific Advisor Board is chaired by Robin Carhart-Harris, PhD, a preeminent, global expert on the clinical application of psychedelics.

We are on the cusp of initiating several Phase 2a clinical trials

